Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cynata Therapeutics Limited (CYP.AX)
Cremorne, VIC, AU
Headquartered in Cremorne, Australia, Cynata Therapeutics Limited, established in 2003 and formerly known as Eco Quest Limited until its 2013 rebranding, specializes in the development and commercialization of its proprietary Cymerus mesenchymal stem cell technology for human therapeutic applications. Its most advanced therapeutic candidate, CYP-001, has successfully concluded Phase I clinical trials for graft versus host disease. The company's pipeline also includes CYP-004, currently in Phase III trials for osteoarthritis treatment, and CYP-006TK, an innovative polymer-coated silicon wound dressing designed for diabetic wounds. Furthermore, Cynata is advancing therapies for a broad spectrum of conditions such as asthma, heart attacks, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata maintains a crucial strategic alliance with Fujifilm, which is responsible for the clinical and commercial manufacturing and supply of its Cymerus therapeutic mesenchymal stem cell products.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.80% | +0.00% | -13.18% | -23.29% | -1.75% | -18.84% | +55.56% | +93.10% | -49.55% | -21.99% | -89.19% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-18.6% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+15.5% Q4'25: +54.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-390.7%
-
EBIT margin Biotechnology: +0.0%-509.8%
-
ROIC Biotechnology: -16.1%-1,031.2% Q4'25: -1,350.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+14.1% Q4'25: +30.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
285.6K
est: 300.0K (-4.8%)
|
1.10M
est: 1.00M (+10.0%)
|
1.75M
est: 25.4K (+6,785.9%)
|
1.38M
est: 77.1K (+1,682.6%)
|
7.01M
est: 4.53M (+54.9%)
|
1.55M
est: 1.47M (+5.3%)
|
7.77M
est: 8.30M (-6.4%)
|
1.65M
est: 3.70M (-55.3%)
|
1.89M
est: 1.80M (+4.7%)
|
1.70M
1.70M – 1.70M
-5.6% YoY
|
31.40M
31.40M – 31.40M
+1,747.1% YoY
|
2.20M
2.20M – 2.20M
-93.0% YoY
|
| EBITDA |
-3.55M
est: -286.3K (-1,138.4%)
|
-5.59M
est: -954.4K (-485.9%)
|
-6.02M
est: -24.2K (-24,746.1%)
|
-5.61M
est: -73.6K (-7,526.8%)
|
-5.87M
est: -4.32M (-35.9%)
|
-8.80M
est: -1.40M (-528.0%)
|
-6.00M
est: -7.92M (+24.3%)
|
-15.65M
est: -3.53M (-343.2%)
|
-9.33M
est: -1.72M (-443.0%)
|
-1.62M
-1.62M – -1.62M
+5.6% YoY
|
-29.97M
-29.97M – -29.97M
-1,747.1% YoY
|
-2.10M
-2.10M – -2.10M
+93.0% YoY
|
| EBIT |
-3.99M
est: -288.5K (-1,284.4%)
|
-5.87M
est: -961.6K (-510.7%)
|
-6.30M
est: -24.4K (-25,706.3%)
|
-5.89M
est: -74.2K (-7,847.1%)
|
-6.15M
est: -4.35M (-41.3%)
|
-9.08M
est: -1.41M (-543.1%)
|
-6.28M
est: -7.98M (+21.3%)
|
-15.93M
est: -3.56M (-347.8%)
|
-9.61M
est: -1.73M (-455.3%)
|
-1.63M
-1.63M – -1.63M
+5.6% YoY
|
-30.19M
-30.19M – -30.19M
-1,747.1% YoY
|
-2.12M
-2.12M – -2.12M
+93.0% YoY
|
| Net Income |
-3.71M
est: -13.08M (+71.6%)
|
-4.94M
est: -14.30M (+65.5%)
|
-4.55M
est: -9.79M (+53.5%)
|
-4.57M
est: -11.79M (+61.3%)
|
-3.64M
est: -14.30M (+74.6%)
|
-7.69M
est: -15.54M (+50.5%)
|
-5.45M
est: -1.23M (-342.8%)
|
-14.28M
est: -7.79M (-83.3%)
|
-9.39M
est: -7.99M (-17.5%)
|
-4.51M
-4.51M – -4.51M
+43.6% YoY
|
-6.76M
-6.76M – -6.76M
-50.0% YoY
|
-18.04M
-18.04M – -18.04M
-166.7% YoY
|
| SGA |
1.84M
est: 489.9K (+274.8%)
|
1.75M
est: 1.63M (+6.9%)
|
2.58M
est: 41.5K (+6,119.7%)
|
2.63M
est: 126.0K (+1,988.1%)
|
2.94M
est: 7.39M (-60.2%)
|
4.49M
est: 2.40M (+87.4%)
|
4.06M
est: 13.55M (-70.0%)
|
3.23M
est: 6.04M (-46.5%)
|
2.33M
est: 2.94M (-20.8%)
|
2.78M
2.78M – 2.78M
-5.6% YoY
|
51.28M
51.28M – 51.28M
+1,747.1% YoY
|
3.59M
3.59M – 3.59M
-93.0% YoY
|
| EPS |
-0.06
est: -0.06 (+4.2%)
|
-0.07
est: -0.07 (+2.6%)
|
-0.06
est: -0.05 (-18.7%)
|
-0.05
est: -0.06 (+12.8%)
|
-0.03
est: -0.07 (+50.3%)
|
-0.06
est: -0.08 (+22.2%)
|
-0.04
est: -0.01 (-533.3%)
|
-0.10
est: -0.04 (-158.9%)
|
-0.05
est: -0.04 (-17.4%)
|
-0.02
-0.02 – -0.02
+43.6% YoY
|
-0.03
-0.03 – -0.03
-50.0% YoY
|
-0.09
-0.09 – -0.09
-166.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kilian Kelly | MD, Chief Executive Officer & Director | 508.8K | — |
| Mathias Kroll | Chief Business Officer | 390.6K | — |
| Jolanta Airey | Chief Medical Officer | 380.3K | — |
| Peter Gordon Webse FCIS FCPA FGIA | Company Secretary | 140.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CYP.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
